
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Recipient : Ginkgo Bioworks
Deal Size : Undisclosed
Deal Type : Collaboration
Ginkgo Bioworks, STRM.BIO, UBC Develop In Vivo CAR Therapies with ARPA-H's EMBODY Program
Details : The collaboration aims to advance cell & gene therapy for autoimmune diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 23, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Ginkgo Bioworks
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : National Center for Advancing Translational Sciences
Deal Size : $2.1 million
Deal Type : Funding
Details : STRM.BIO has developed a proprietary, large capacity EV-based therapy for in vivo nucleic acid and protein delivery that specifically targets hematopoietic stem cells (HSCs) in bone marrow, is amenable to large scale commercial manufacture and presents w...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : National Center for Advancing Translational Sciences
Deal Size : $2.1 million
Deal Type : Funding
